- Home
- AGIO vs MTX Comparison
AGIO vs MTX Comparison
Compare AGIO & MTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- MTX
- Stock Information
- Founded
- AGIO 2007
- MTX 1968
- Country
- AGIO United States
- MTX United States
- Employees
- AGIO N/A
- MTX N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- MTX Major Chemicals
- Sector
- AGIO Health Care
- MTX Industrials
- Exchange
- AGIO Nasdaq
- MTX Nasdaq
- Market Cap
- AGIO 2.1B
- MTX 2.0B
- IPO Year
- AGIO 2013
- MTX 1992
- Fundamental
- Price
- AGIO $36.39
- MTX $63.55
- Analyst Decision
- AGIO Buy
- MTX Strong Buy
- Analyst Count
- AGIO 6
- MTX 2
- Target Price
- AGIO $57.00
- MTX $82.00
- AVG Volume (30 Days)
- AGIO 771.2K
- MTX 209.5K
- Earning Date
- AGIO 10-30-2025
- MTX 10-23-2025
- Dividend Yield
- AGIO N/A
- MTX 0.69%
- EPS Growth
- AGIO N/A
- MTX N/A
- EPS
- AGIO 11.13
- MTX 0.06
- Revenue
- AGIO $40,875,000.00
- MTX $2,063,500,000.00
- Revenue This Year
- AGIO $28.19
- MTX N/A
- Revenue Next Year
- AGIO $152.14
- MTX $4.53
- P/E Ratio
- AGIO $3.27
- MTX $1,019.53
- Revenue Growth
- AGIO 30.57
- MTX N/A
- 52 Week Low
- AGIO $23.42
- MTX $49.54
- 52 Week High
- AGIO $62.58
- MTX $86.49
- Technical
- Relative Strength Index (RSI)
- AGIO 51.16
- MTX 52.03
- Support Level
- AGIO N/A
- MTX N/A
- Resistance Level
- AGIO $37.18
- MTX $65.19
- Average True Range (ATR)
- AGIO 1.43
- MTX 1.47
- MACD
- AGIO -1.50
- MTX -2.57
- Stochastic Oscillator
- AGIO 88.53
- MTX 95.97
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About MTX Minerals Technologies Inc.
Minerals Technologies Inc mines, produces, and sells mineral-based products. The firm organizes itself into two segments: The Consumer & Specialties segment that derives maximum revenue, serves consumer end markets directly with mineral-to-market finished products and also provides specialty mineral-based solutions and technologies that are an essential component of its customers' finished products. The Engineered Solutions segment serves industrial end markets with engineered systems, mineral blends, and technologies that are designed to improve its customers' manufacturing processes and projects. The majority of revenue comes from the United States.